Retains PCG Advisory to Build Wall Street Awareness
HALIFAX, NOVA SCOTIA, Mar 16, 2015 (Marketwired via COMTEX) -- Immunovaccine Inc. ("Immunovaccine" or "IMV") (IMV), a clinical stage vaccine and immunotherapy company, today announced that it is seeking approval to have its common shares trade on the OTCQX(R) Best Marketplace. The trading of Immunovaccine's common shares on OTCQX is subject to review and approval by OTC Markets Group Inc. Immunovaccine's shares will continue to trade on the Toronto Stock Exchange under the symbol "IMV."
"During the past year, we have steadily increased awareness in the United States of the Company's programs in immunotherapy and infectious disease. The OTCQX qualification would provide trading access for US-based investors as we continue to build our visibility across North America," stated Dr. Marc Mansour, chief executive officer of Immunovaccine.
Immunovaccine has retained the services of New York City based PCG Advisory Group to provide strategic services across the US. Founded in 2008, PCG Advisory Group is dedicated to the delivery of top tier investor relations, strategic and tactical digital and social media communications, and cutting edge media and public relations for public and privately held companies. Neither PCG Advisory Group nor any of its principals have an ownership interest, directly or indirectly, in Immunovaccine or its securities, nor has the Company granted PCG Advisory Group or its principals any rights to acquire any such interests.
About DepoVax(TM)
DepoVax(TM) is a patented formulation that provides controlled and prolonged exposure of antigens plus adjuvant to the immune system, resulting in a strong, specific and sustained immune response with the potential for single-dose effectiveness. The DepoVax platform is flexible and can be used with a broad range of target antigens for preventative or therapeutic applications. The technology is designed to be commercially scalable, with the potential for years of shelf life stability.
About Immunovaccine
Immunovaccine Inc. develops cancer immunotherapies and infectious disease vaccines based on the Company's DepoVax(TM) platform, a patented formulation that provides controlled and prolonged exposure of antigens and adjuvant to the immune system. Immunovaccine has advanced two T cell activation therapies for cancer through Phase I human clinical trials. Lead cancer vaccine therapy, DPX-Survivac, is expected to enter Phase II clinical studies in both ovarian cancer and glioblastoma (brain cancer), with Immunovaccine also exploring additional studies in other indications including lymphoma and recurrent ovarian cancer. The Company is also advancing an infectious disease pipeline, including innovative vaccines for respiratory syncytial virus (RSV), anthrax and Ebola virus.
Connect at www.imvaccine.com.
This press release contains forward-looking information under applicable securities law. All information that addresses activities or developments that we expect to occur in the future, is forward-looking information. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. However, they should not be regarded as a representation that any of the plans will be achieved. Such statements include but are not limited to statements about the benefits of being quoted on the OTCQX Best Marketplace and the possibility that Immunovaccine will be accepted for quotation on the OTCQX marketplace. Actual results may differ materially from those set forth in this press release due to risks affecting the company, including access to capital, the successful completion of clinical trials and receipt of all regulatory approvals. Immunovaccine Inc. assumes no responsibility to update forward-looking statements in this press release except as required by law.
Neither TSX Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contacts:
Immunovaccine Inc.
Dr. Marc Mansour
Chief Executive Officer
(902) 492-1819
www.imvaccine.com
Vida Strategic Partners (media)
Tim Brons
(415) 675-7402
SOURCE: Immunovaccine Inc.
(C) 2015 Marketwire L.P. All rights reserved.